REVLIMID® Provides Responses For Patients With Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma, Preliminary Study Results

June 15th, 2008 | Category: Cancer

Celgene universal Sárl (Nasdaq:CELG) today announced that preliminary info from an worldly study of singled-out agent REVLIMID (lenalidomide) in relapsed/refractory aggressive non-Hodgkin’s lymphoma (NHL) were presented at the 13th Congress of the European

Hematology organization (EHA) in Copenhagen, Denmark. In that study of heavily pretreated patients, 83 were eligible for response evaluation.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Results Of A Phase 3 Study Show TORISEL Significantly Improved Progression-free Survival For Patients With Relapsed/refractory Mantle Cell Lymphoma
  • Revlimid Improves Survival For Multiple Myeloma Patients
  • Seattle Genetics Reports Multiple Complete And Partial Responses With SGN-35 In Patients With Lymphoma
  • New Study Shows Environmental Contaminants Increase Risk Of Non-Hodgkin Lymphoma, Canada
  • ZOLINZA (vorinostat) With Bortezomib Demonstrated Clinical ActivityIn Investigational Studies Of Patients With Advanced Multiple Myeloma

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.